NPC2 and hepatocellular carcinoma: Since the Ras/Raf/MEK/ERK signaling pathway is the main target by which sorafenib inhibits the proliferation of HCC cells [29], we next evaluated whether NPC2 secretion is responsible for inhibition of this pathway.